Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(5-Isopropyl-thiazol‐2‐YL)‐2‐pyridin‐3‐YL‐acetamide is a synthetic small molecule belonging to the class of pyridine derivatives. It features a thiazole ring substituted with an isopropyl group and an acetamide linker to a pyridine moiety. The compound has been identified as an inhibitor of cyclin-dependent kinase 2 (CDK2), which plays a key role in cell cycle regulation by controlling the transition from G1 to S phase. By inhibiting CDK2 activity, this molecule may have potential applications in cancer research or other proliferative disorders where CDK dysregulation is implicated[1][8]. There are no known approved therapeutic indications or marketed formulations for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(5-Isopropyl-thiazol-2-yl)-2-pyridin-3-yl-acetamide.